Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03172975 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03172975 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 39 participants.
The verdict
NCT03172975, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
Interventions
- BIOLOGICAL Placebo
- DRUG Albendazole
- BIOLOGICAL Na-GST-1/Alhydrogel
- BIOLOGICAL Na-GST-1/Alhydrogel + CPG 10104
- BIOLOGICAL Na-GST-1/Alhydrogel + GLA-AF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03172975
The ClinicalTrials.gov registry entry for NCT03172975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03172975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03172975 about?
NCT03172975 is a clinical study titled "Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection". This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
What is the current status of trial NCT03172975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-03-01. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT03172975?
The interventions under investigation include: Placebo (BIOLOGICAL), Albendazole (DRUG), Na-GST-1/Alhydrogel (BIOLOGICAL), Na-GST-1/Alhydrogel + CPG 10104 (BIOLOGICAL), Na-GST-1/Alhydrogel + GLA-AF (BIOLOGICAL).
Who is sponsoring clinical trial NCT03172975?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.